Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 3/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9500277 | 0.81 | ENPP1 (0.40) | ENPP1CCNA2CDK2CCNA1CDK1 | |
| SCHEMBL9500288 | 0.81 | PNP (0.41) | PNPENPP1FGFR1FGFR2 | |
| SCHEMBL10383666 | 0.80 | CDK1 (0.47) | PNPENPP1CCNA2CDK2CCNA1 | |
| SCHEMBL6424961 | 0.74 | PNP (0.48) | PNPCCNA2CDK2FGFR1FGFR2 | |
| SCHEMBL3396382 | 0.73 | PNP (0.52) | PNP | |
| SCHEMBL4481885 | 0.71 | CCNA2 (0.39) | PNPCCNA2CDK2CCNA1CDK1 | |
| SCHEMBL1251786 | 0.71 | — | — | |
| Methylguanine SCHEMBL29903462 | 0.70 | CDK1 (0.69) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| Methylguanine SCHEMBL231097 | 0.70 | CDK1 (0.69) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| SCHEMBL7453052 | 0.70 | CCNA2 (0.36) | CCNA2CDK2CCNA1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101351559-A | Multiplexed quantitative detection of pathogens | PRIMERA BIOSYSTEMS INC (US) | 2009-01-21 | — | — | CN | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| US-7034007-B1 | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion | EAST CAROLINA UNIVERSITY (US) | 2006-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | PNP 2312/4885ENPP1 947/4885CCNA2 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.